Fig. 5
PARPi suppress the growth of BLCA xenografts in vivo. Xenografts of UM-UC-3 cells in SCID mice were generated by injecting 2x106 cells into both flanks of SCID mice (n = 5/group). When the tumor volumes reached ~100 mm3, mice were treated with the PARPi niraparib (A), olaparib (B), rucaparib (C), talazoparib (D) or a combination of PARPi with cisplatin as detailed in the Methods section. Tumor growth was monitored using digital calipers. Toxicity was assessed by weighing the mice twice a week. At the end of the experiment, tumor tissues were harvested, and tumor inhibition was calculated as percentage tumor growth inhibition compared with vehicle control. E Average body weights±SD of all mice in each group are shown